Additionally, Infervision’s technology and a group of radiologists recently went head-to-head in a report reading experiment with different types and sizes of nodules. Infervision’s AI-CT predicted more accurately than radiologists in every category.

“In no way will this technology ever replace doctors. It is intended to eliminate much of the highly repetitive work. Infervision empowers doctors and helps them deliver more accurate reports and do it much faster,” continued Kuan.


The Infervision artificial intelligence continues to learn as more data becomes available and also analyzes past results. Lung cancer is particularly rampant in China due to both air pollution and smoking with between 600,000 and 700,000 new lung cancer cases are diagnosed annually. While this is an unfortunate statistic, it provides a huge trove of medical data that can make the Infervision technology stronger and even more effective.


About Infervision
Infervision specializes in assisted medical image diagnosis, using artificial intelligence and deep learning to help improve the workflow and efficiency of radiologists for diagnosing various types of cancer and other diseases. The company has raised a Series A round of 50M RMB ($7.2M USD) led by Sequoia Capital and established cooperative business partnerships with close to 20 Tertiary Grade A hospitals including Peking Union Medical College Hospital and Shanghai Changzheng Hospital. It also has relationships with online and offline medical image platforms including Ali Cloud Computing and has entered into strategic partnerships with GE Healthcare, Cisco and NVIDIA. Founders and scientists with Infervision studied at top universities and research institutions around the world. For more information visit www.infervision.com.

Back to HCB News

Health IT Homepage